long intergenic non-protein coding RNA 863Genealiases: []
Q-omics provides the consensus-scored LINC00863 profile across patient tissues and cancer cell-line models. LINC00863 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC00863 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LINC00863 RNA expression shows 19,946 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where LINC00863 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00863 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00863 survival associations across molecular data types. LINC00863 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00863 RNA expression–survival associations across cancer types. High LINC00863 expression shows unfavorable associations in ACC and LUSC, but favorable associations in THYM, BRCA, LGG and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC00863 RNA expression.
This table summarizes LINC00863 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00863. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00863 shows lower tumor expression in KIRC, KICH, THCA and COAD and higher tumor expression in HNSC and LIHC. The KIRC box plot shows higher LINC00863 RNA expression in normal versus tumor tissue (log2 FC = −0.672, t-test p < 0.001).
This table shows molecular features associated with LINC00863 in patient tissues and cancer cell lines. In patient samples, LINC00863 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
